Denosumab for the treatment of bisphosphonate-refractory hypercalcemia

Journal of Clinical Oncology

Volumn 30, Issue 29, 2012, Pages

  Boikos, Sosipatros A ^a   Hammers, Hans Joerg ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM; DENOSUMAB; ZOLEDRONIC ACID;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; CONFUSION; DEHYDRATION; HUMAN; HYDRATION; HYPERCALCEMIA; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; DISEASE PROGRESSION; DRUG RESISTANCE; FATAL OUTCOME; HUMANS; HYPERCALCEMIA; IMIDAZOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PARATHYROID HORMONE; RISK ASSESSMENT;

EID: 84867606008     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.7923     Document Type: Article

References (5)

1. Baron R, Ferrari S, Russell RG: Denosumab and biphosponates: Different mechanisms of action and effects. Bone 48:677-692, 2011
2. Fizazi K, Carducci M, Smith M, et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377:813-822, 2011
3. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
4. Henry DH, Costa L, Goldwasser F, et al: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132, 2011
5. Hu MI, Gucalp R, Insogna KL, et al: A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates. J Clin Oncol 29:43s, 2011 (suppl 15; abstr TPS245)